The future of the global interventional cardiology and peripheral vascular device market looks promising with opportunities in the hospitals and ambulatory surgical centers markets.
- Within the type category, interventional cardiology devices will remain the largest segment over the forecast period as the increasing demand for minimally invasive cardiac procedures.
- Within the end use category, hospitals will remain the largest segment due to the increasing demand for advanced cardiovascular treatments.
- In terms of regions, North America will remain the largest region over the forecast period due to the growing prevalence of cardiovascular diseases.
Emerging Trends in Interventional Cardiology and Peripheral Vascular Device Market
The interventional cardiology and peripheral vascular device market is evolving through catheter innovation, drug delivery technologies, improved imaging, and minimally invasive treatment approaches during 2025 and 2026. Lucintel identifies clinical performance, regulatory progress, and broader access to specialized cardiovascular care as important influences on market development.- Drug Coated Balloon Expansion: Cordis received FDA approval for its SELUTION SLR coronary drug eluting balloon in September 2026, offering sustained sirolimus delivery without a permanent implant. This approach may expand treatment choices for coronary restenosis over the next three to five years.
- Advanced Thrombectomy Technologies: Medtronic introduced commercial use of its Liberant thrombectomy system in December 2025 for removing vascular clots. These systems can broaden minimally invasive treatment options and support demand for specialized peripheral vascular procedures.
- Integrated Embolic Protection: Medtronic expanded distribution of its Neuroguard IEP system in October 2025, combining a stent, dilation balloon, and filter in one device. Integrated designs may simplify carotid procedures and strengthen demand for multifunctional vascular technologies.
- Clinical Evidence Driven Adoption: Medtronic reported 70.2 percent target lesion primary patency at 12 months for its IN.PACT AV drug coated balloon study in April 2026, based on 17 United States clinical sites. Such evidence may influence physician confidence and purchasing decisions.
- Precision Intravascular Imaging: The FDA cleared Boston Scientific’s OptiCross coronary imaging catheter range in April 2026. Improved intravascular visualization can help clinicians assess vessel characteristics and guide interventions, supporting greater use of imaging assisted procedures over the next three to five years.
Recent Developments in the Interventional Cardiology and Peripheral Vascular Device Market
The interventional cardiology and peripheral vascular device market has experienced strategic acquisitions, regulatory clearances, and new catheter technologies during 2024 and 2025. Lucintel tracks how these developments are reshaping product portfolios, competitive positioning, and access to minimally invasive cardiovascular treatments across healthcare systems.- Peripheral Vascular Portfolio Acquisition: In June 2024, Boston Scientific agreed to acquire Silk Road Medical for approximately USD 1.16 billion. The transaction adds transcarotid artery revascularization technology for stroke prevention, strengthening its vascular portfolio and expanding opportunities in minimally invasive carotid treatment.
- Intravascular Lithotripsy Investment: In January 2025, Boston Scientific announced an agreement to acquire Bolt Medical, involving an upfront payment of USD 443 million and potential additional payments of USD 221 million. The technology targets calcified coronary and peripheral lesions, potentially broadening treatment options over the next five years.
- Ultrasound Based Renal Denervation: In March 2025, Boston Scientific agreed to acquire SoniVie, offering approximately USD 360 million upfront and up to USD 180 million tied to regulatory milestones. Its investigational TIVUS system expands the company’s hypertension treatment pipeline, creating potential for future catheter based interventions.
- Expanded Balloon Catheter Portfolio: In March 2025, BrosMed received United States Food and Drug Administration clearance for three next generation peripheral angioplasty balloon models, offering more than 2,000 configurations. The expanded range supports tailored treatment of peripheral artery disease and may strengthen competition through product variety.
- Multifunctional Catheter Clearance: In July 2024, the FDA cleared BIOTRONIK’s Oscar Peripheral Multifunctional Catheter system. The regulatory decision supports commercial availability of a specialized peripheral angioplasty device, potentially expanding procedural options and reinforcing demand for versatile intervention tools.
Strategic Growth Opportunities in the Interventional Cardiology and Peripheral Vascular Device Market
The interventional cardiology and peripheral vascular device market is creating commercial opportunities through advanced catheter therapies, mechanical thrombectomy, vascular imaging, and treatments for complex arterial disease. Lucintel tracks how acquisitions, clinical development, and regulatory progress are expanding product portfolios and future commercialization potential.- Mechanical Thrombectomy Expansion: In January 2026, Boston Scientific agreed to acquire Penumbra for approximately USD 14.5 billion, expanding access to clot removal technologies. Broader thrombectomy portfolios could generate revenue across peripheral vascular procedures and adjacent neurovascular applications over the next three to five years.
- Intravascular Lithotripsy Development: In January 2025, Boston Scientific agreed to acquire Bolt Medical, strengthening its coronary and peripheral intravascular lithotripsy portfolio. Expanding treatment options for heavily calcified arteries could increase demand for specialized balloon catheter systems.
- Renal Denervation Technologies: In March 2025, Boston Scientific announced a SoniVie acquisition agreement involving USD 360 million upfront and up to USD 180 million in regulatory milestone payments. Successful clinical validation could create new revenue opportunities in catheter based hypertension treatment, subject to regulatory authorization.
- Drug Coated Balloon Applications: In 2025, Boston Scientific initiated the AGENT DCB STANCE clinical trial to investigate broader use of its coronary drug coated balloon beyond in stent restenosis. Positive results could expand eligible patient populations and increase demand for implant free coronary interventions over the coming years.
- Advanced Vascular Embolization Devices: In January 2026, the FDA cleared Medtronic’s Concerto Versa detachable coil through its 510(k) pathway. Further innovation in embolization technologies creates opportunities to address complex vascular conditions and broaden specialized interventional device portfolios.
Interventional Cardiology and Peripheral Vascular Device Market Drivers and Challenges
The interventional cardiology and peripheral vascular device market is influenced by rising demand for minimally invasive cardiovascular procedures, technological innovation, an aging population, and expanding access to specialized care. Lucintel recognizes product development, clinical evidence, affordability, and regulatory requirements as important factors influencing commercial adoption. Growth also depends on hospital investment, reimbursement policies, physician training, and manufacturers’ ability to demonstrate safety, effectiveness, and long term clinical value.The factors responsible for driving the interventional cardiology and peripheral vascular device market include:
- Minimally Invasive Procedures: Rising preference for catheter based treatment supports demand. Medtronic introduced Liberant in December 2025 for mechanical thrombectomy, expanding treatment options. Adoption should increase through 2030.
- Device Innovation: Advanced balloon catheters improve procedural precision. The FDA cleared Bard Peripheral Vascular’s UltraScore device in February 2026, supporting treatment innovation. Innovation should strengthen product demand.
- Cardiovascular Disease Burden: Persistent vascular disease increases intervention needs. In December 2025, Medtronic reported Liberant’s first commercial use, reflecting expanded treatment choices. Wider diagnosis should support demand.
- Aging Population: Older patients face increased cardiovascular risks, encouraging treatment needs. Continued demographic aging should support procedure volumes over three to five years.
- Improved Clinical Outcomes: Targeted devices can improve treatment effectiveness and recovery. In April 2025, the FDA cleared BIOTRONIK’s coronary and peripheral catheter portfolio, broadening available options. Evidence based adoption should continue.
The challenges facing the interventional cardiology and peripheral vascular device market include:
- Regulatory Requirements: Device approvals require substantial safety evidence. Different national requirements increase compliance costs and can delay commercialization.
- High Treatment Costs: Specialized devices and catheterization facilities require considerable investment. Budget constraints may restrict adoption in lower income healthcare systems.
- Clinical Risks: Bleeding, restenosis, infection, and device complications can affect outcomes. Manufacturers must demonstrate safety and long term effectiveness to sustain clinician confidence.
List of Interventional Cardiology and Peripheral Vascular Device Market Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies interventional cardiology and peripheral vascular device market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base.Some of the interventional cardiology and peripheral vascular device market companies profiled in this report include:
- Abbott Laboratories
- Boston Scientific Corporation
- Edwards Lifesciences Corporation
- Medtronic Public Limited Company
- C. R. Bard, Inc.
- Cook Medical Inc.
- Terumo Corporation
Interventional Cardiology and Peripheral Vascular Device Market by Segment
The study includes a forecast for the global interventional cardiology and peripheral vascular device market by type, device, end use, and region.Type [Value ($B) from 2019 to 2035]:
- Interventional Cardiology Devices
- Peripheral Vascular Devices
Device [Value ($B) from 2019 to 2035]:
- Angioplasty Balloons
- Angioplasty Stents
- Angioplasty Catheters
- EVAR Stent Graft
- IVC Filter
- Embolic Protection Devices
- Guidewires
- Arteriotomy Closure Devices
- Intravascular Ultrasound System
- Synthetic Surgical Graft
End Use [Value ($B) from 2019 to 2035]:
- Hospitals
- Ambulatory Surgical Centers
Region [Value ($B) from 2019 to 2035]:
- North America
- Europe
- Asia Pacific
- The Rest of the World
Country Wise Outlook for the Interventional Cardiology and Peripheral Vascular Device Market
The interventional cardiology and peripheral vascular device market is advancing through minimally invasive treatment technologies, catheter innovations, and improved vascular access solutions. Lucintel tracks developments across established medical device manufacturers and emerging innovators as regulatory approvals and strategic partnerships reshape commercialization opportunities.- United States: In June 2024, the Food and Drug Administration approved Cordis Corporation’s MYNX CONTROL venous vascular closure device for closing femoral vein puncture sites after catheterization. This approval expands available vascular closure options and supports the adoption of minimally invasive cardiovascular procedures.
- China: In February 2025, BrosMed Medical and Cordis signed an exclusive distribution agreement for the VaSecure drug coated peripheral balloon catheter in China. The agreement combines local product innovation with an established commercial network, potentially broadening access to advanced peripheral artery disease treatments.
- Germany: In February 2025, BIOTRONIK announced an agreement to divest its vascular intervention division to Teleflex Incorporated as part of a strategic shift toward active implantable devices and digital healthcare. The transaction signals portfolio consolidation within cardiovascular technology and may reshape competitive positioning in vascular intervention products.
- India: In May 2025, the Technology Development Board, under the Department of Science and Technology, announced financial support for S3V Vascular Technologies to establish an integrated manufacturing facility for mechanical thrombectomy kits at the Medical Devices Park in Oragadam, Tamil Nadu. The initiative supports domestic production of advanced vascular intervention devices and reduces reliance on imported technologies.
- Japan: In May 2024, Japan’s Pharmaceuticals and Medical Devices Agency documented approval of Medtronic Japan’s PulseSelect pulsed field ablation catheter and generator. The technology supports catheter based treatment of atrial fibrillation, broadening minimally invasive cardiac treatment options and strengthening access to advanced electrophysiology devices.
Features of the Global Interventional Cardiology and Peripheral Vascular Device Market
- Market Size Estimates: Interventional cardiology and peripheral vascular device market size estimation in terms of value ($B).
- Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
- Segmentation Analysis: Interventional cardiology and peripheral vascular device market size by various segments, such as by type, device, end use and region in terms of value ($B).
- Regional Analysis: Interventional cardiology and peripheral vascular device market breakdown by North America, Europe, Asia Pacific, and the Rest of the World.
- Growth Opportunities: Analysis of growth opportunities in different type, device, end use and regions for the interventional cardiology and peripheral vascular device market.
- Strategic Analysis: This includes M&A, new product development, and competitive landscape of the interventional cardiology and peripheral vascular device market.- Analysis of competitive intensity of the industry based on Porter's Five Forces model.
This report answers the following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the interventional cardiology and peripheral vascular device market by type (interventional cardiology devices and peripheral vascular devices), device (angioplasty balloons, angioplasty stents, angioplasty catheters, EVAR stent graft, IVC filter, embolic protection devices, guidewires, arteriotomy closure devices, intravascular ultrasound system, and synthetic surgical graft), end use (hospitals and ambulatory surgical centers), and region (North America, Europe, Asia Pacific, and the Rest of the World)?Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 8 years, and what has its impact been on the industry?
This product will be delivered within 1-3 business days.
Table of Contents
Companies Mentioned
- Abbott Laboratories
- Boston Scientific Corporation
- Edwards Lifesciences Corporation
- Medtronic Public Limited Company
- C. R. Bard, Inc.
- Cook Medical Inc.
- Terumo Corporation
Methodology
The analyst has been in the business of market research and management consulting since 2000 and has published over 600 market intelligence reports in various markets/applications and served over 1,000 clients worldwide. Each study is a culmination of four months of full-time effort performed by the analyst team. The analysts used the following sources for the creation and completion of this valuable report:
- In-depth interviews of the major players in the market
- Detailed secondary research from competitors’ financial statements and published data
- Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
- A compilation of the experiences, judgments, and insights of professionals, who have analyzed and tracked the market over the years.
Extensive research and interviews are conducted in the supply chain of the market to estimate market share, market size, trends, drivers, challenges and forecasts.
Thus, the analyst compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. The analyst then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process.

LOADING...

